FRAME: Framework for Real-World Evidence Assessment to Mitigate Evidence Uncertainties for Efficacy/Effectiveness - An Evaluation of Regulatory and Health Technology Assessment Decision Making. [PDF]
Clin Pharmacol TherCandore G +12 more
europepmc +1 more source
What do European clinical guidelines say about genetic testing for people with neuropsychiatric disorders? A scoping review. [PDF]
Psychiatr GenetArican I +3 more
europepmc +1 more source
Access to anticancer and orphan medicines through compassionate use programs and named patient basis in seven European countries. [PDF]
ESMO OpenRosenberg N +7 more
europepmc +1 more source
How Patients Can Contribute to the Assessments of Health Technologies. [PDF]
J Mark Access Health PolicyHouÿez F, Delaye J.
europepmc +1 more source
Bulletin mensuel d'information = Monthly bulletin of information. No. 4, July 1958 [PDF]
, 1958 core
Therapeutic innovation in oncology: What do you mean? Whereof one cannot speak, thereof one must be silent, L. Wittgenstein. [PDF]
BMC CancerChevret S +4 more
europepmc +1 more source
ECSC Porte-parole information rapide. Résultat de la 680ème séance de la Haute Autorité.= ECSC Spokesman Service Rapid Information. Results of the 680th session of the High Authority. 28/62. 4 May 1962 [PDF]
, 1962 core
Catheter Ablation for Atrial Fibrillation in Breast Cancer Survivors: An Exploratory Observational Study Using the French Nationwide Health Care Database Sample. [PDF]
Cancer Rep (Hoboken)Saint-Lary L +7 more
europepmc +1 more source
Débats de l'Assemblée Commune. Compte rendu in extenso des séances. No 36. Exercice 1957-1958. Deuxième session extraordinaire, séance du mercredi 26 février 1958. = Debates of the Common Assembly. Proceedings of the sessions. No. 36. Year 1957-1958. Second Extraordinary Session, sitting of Wednesday, 26 February 1958 [PDF]
, 1958 core
Complications and Risk Factors of Neurogenic Bladder: A Delphi Consensus. [PDF]
Eur Urol Open SciTurmel N +5 more
europepmc +1 more source